ABT ABBOTT LABORATORIES

2026Q2 · CUSIP 002824100 · Sector: Healthcare & Biotech

Normal

Fund flows are within the usual range

Funds that own it

2,904

Institutions that reported holding it to the SEC

Net decrease in holders

196

Last quarter 3,100 → now 2,904

How unusual is that

Bottom 20%

Among the weakest buying in the market

What the filings say, in one paragraph

2,904 funds held ABT at the end of 2026Q2, down 196 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $45.1B(YoY +6.6%), the P/E is 30.9x, return on equity is 12.1%. ABT has had 31 buying rushes in its history, and the price moved +7.9% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

What happened after each past buying rush 31 times in its history

Quarter of the rush	How unusual then	Price, next 3 months	Price, next 6 months
2025Q4	Top 5%	-20.7%	—
2025Q2	Top 20%	+0.7%	-12.2%
2025Q1	Top 1% in the market	-2.7%	-3.2%
2024Q4	Top 5%	+3.7%	+0.7%
2024Q3	Top 10%	+15.6%	+13.2%
2024Q1	Top 20%	+8.1%	+12.5%
2023Q4	Top 1% in the market	-8.2%	-0.8%
2023Q2	Top 10%	-6.6%	+9.8%
2022Q4	Top 1% in the market	+2.8%	-1.3%
2021Q4	Top 1% in the market	-8.5%	-10.3%
2021Q3	Top 10%	-5.9%	-11.9%
2021Q1	Top 10%	+6.9%	+13.3%
2020Q4	Top 5%	-6.9%	-0.4%
2020Q3	Top 5%	+12.1%	+7.5%
2020Q2	Top 1% in the market	+12.2%	+27.3%
2019Q4	Top 5%	+0.7%	+12.4%
2019Q3	Top 10%	+5.4%	+7.8%
2019Q2	Top 20%	-0.4%	+5.7%
2019Q1	Top 10%	+12.0%	+11.6%
2018Q4	Top 5%	+1.4%	+13.5%
2018Q3	Top 5%	+4.8%	+6.8%
2018Q1	Top 1% in the market	+5.5%	+14.7%
2017Q4	Top 5%	+3.1%	+8.6%
2017Q3	Top 10%	+7.0%	+12.9%
2017Q1	Top 1% in the market	+16.3%	+29.0%
2016Q4	Top 5%	-2.2%	+12.8%
2016Q3	Top 20%	+12.6%	+9.4%
2015Q4	Top 10%	-0.9%	+18.1%
2014Q4	Top 5%	+6.0%	+8.0%
2014Q1	Top 10%	+7.1%	+11.7%
2013Q4	Top 5%	+1.2%	+9.6%

Show all 31 events

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾

Of them, large funds

384

Change in large funds

+28

Total value they hold

$124.5B

Funds buying for the first time

195

Funds that sold out entirely

391

Price change that quarter

+26.6%

Funds holding puts (bearish)

Funds holding calls (bullish)

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)

30.9

EPS (TTM)

$3.57

EPS YoY

-53.6%

Revenue (TTM)

$45.1B

Revenue YoY

+6.6%

Net margin

13.9%

ROE

12.1%

Debt ratio

52.9%

FCF (TTM)

$7.4B

Dividend (TTM)

$2.44

Quarterly Revenue & EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close around day 47 after quarter-end ÷ TTM EPS then; this is a consistent valuation date, not the company’s actual filing date; loss quarters hidden

Quarterly free cash flow

Latest quarter $916M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-03-31 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.